Hana Must SPAC 2 - Asset Resilience Ratio
Hana Must SPAC 2 (208370) has an Asset Resilience Ratio of 18.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Hana Must SPAC 2's Asset Resilience Ratio has changed over time. Check 208370 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Hana Must SPAC 2's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hana Must SPAC 2 market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.80 Billion | 18.07% |
| Total Liquid Assets | ₩12.80 Billion | 18.07% |
Asset Resilience Insights
- Good Liquidity Position: Hana Must SPAC 2 maintains a healthy 18.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hana Must SPAC 2 Industry Peers by Asset Resilience Ratio
Compare Hana Must SPAC 2's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Hana Must SPAC 2 (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Hana Must SPAC 2.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 37.15% | ₩26.09 Billion ≈ $17.68 Million |
₩70.22 Billion ≈ $47.59 Million |
+0.74pp |
| 2023-12-31 | 36.41% | ₩24.28 Billion ≈ $16.45 Million |
₩66.68 Billion ≈ $45.19 Million |
+20.76pp |
| 2022-12-31 | 15.65% | ₩7.06 Billion ≈ $4.79 Million |
₩45.11 Billion ≈ $30.57 Million |
-14.71pp |
| 2021-12-31 | 30.36% | ₩14.87 Billion ≈ $10.08 Million |
₩48.98 Billion ≈ $33.20 Million |
+0.14pp |
| 2020-12-31 | 30.22% | ₩13.64 Billion ≈ $9.24 Million |
₩45.14 Billion ≈ $30.59 Million |
+2.75pp |
| 2019-12-31 | 27.48% | ₩12.94 Billion ≈ $8.77 Million |
₩47.11 Billion ≈ $31.92 Million |
+24.01pp |
| 2018-12-31 | 3.46% | ₩1.43 Billion ≈ $968.25K |
₩41.26 Billion ≈ $27.96 Million |
-2.55pp |
| 2017-12-31 | 6.01% | ₩3.29 Billion ≈ $2.23 Million |
₩54.70 Billion ≈ $37.07 Million |
-4.36pp |
| 2016-12-31 | 10.37% | ₩4.71 Billion ≈ $3.20 Million |
₩45.48 Billion ≈ $30.82 Million |
+10.33pp |
| 2015-12-31 | 0.03% | ₩16.50 Million ≈ $11.18K |
₩47.25 Billion ≈ $32.02 Million |
-- |
About Hana Must SPAC 2
SELVAS Healthcare, Inc. operates as a medical device company in South Korea. The company provides body composition analyzers and automatic blood pressure monitors for hospitals. It also offers Braille Sense notetakers and other products for blind and visually impaired people under the HIMS brand name, as well as provides digital health products under the ACCUNIQ brand name. In addition, The compa… Read more